Comments
Glenmark Pharmaceuticals has said that Glenmark Generics Inc, its US subsidiary, has received final approval from the US health regulator to market its generic Ursodiol tablets, used for treating cirrhosis, in the American market.
Glenmark Generics Inc has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ursodiol tablets USP in strengths of 250 mg and 500 mg, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange.
The company said shipping will commence immediately from its New Jersey facility.
“According to IMS Health, for the 12-month period ending March 2011, total market sales achieved for Ursodiol tablets were $60 million,” it added.
Ursodiol is a generic version of the Urso 250 mg and Urso Forte tablets developed by Axcan, Glenmark said.
“The company’s current portfolio consists of 70 generic products authorised for distribution in the US market and approximately 40 ANDAs filed with the USFDA pending approval,” it added.
The company scrip was trading at Rs 321.75 apiece in the afternoon trade on the BSE today, up 2.55 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.